Archive

3H Medi Solution (formerly CROee INC), Japan, in furtherance with its organizational goals, recently had table talks with its prospective associate, Keio University Hospital, represented by Dr. Kenzo Soejima (MD Ph.D.), Director of Clinical and Translational Research Center at the University, wherein Dr. Soejima spoke about the ongoing activities and forward trends in Clinical Trials, […]

At present several clinical trials are conducted for the treatment of certain Lysosomal Storage Diseases (LSD) but faced with multiple challenges.one such challenge is that the results of ERT are not promising. Enzyme Replacement Therapy (ERT) is primarily used in LSD treatments, however the progress has not been satisfactory in some of the LSDs like […]

Earlier in this month of April, CROèe’s Oncology Team recently organized a felicitation seminar in Kyoto in honor of the Year 2018 Noble Laureate, Professor Honjo Tasuku, wherein the Noble Laureate received accolades for his outstanding work in the oncology field. Additionally, he was also thanked for saving and altering the lives of numerous cancer […]

AstraZeneca K.K. (“AstraZeneca,” Head Office: Kita-ku Osaka-shi, President: Stefan WoxströmA) and CROèe Inc. (“CROèe,” Head Office: Toshima-ku Tokyo, President: Sho Ando) surveyed patients with advanced or recurrent non-small cell lung cancer on their attitudes toward medication. With an increasing number of options, treatment of advanced and recurrent non-small cell lung cancer is becoming more complicated. […]

As a result of having the largest population, China is a country with the highest number of potential patients. Unfortunately, China’s patient pool remains largely untapped due to several country-specific challenges and obstacles. One of the major issues is the lack of widespread awareness within the general Chinese population regarding the clinical trials. Even the […]

As a Patient recruitment specialised Tokyo based PRO-cum-CRO, CROee got an access to a massive database of over 20 million registered patients from more than 400 sites in Japan other than its own 810,000 registered patient under CROee Database. The database includes details of patient’s medical history, hospitalisation-history, symptoms of the disease, participated clinical trials […]

 In Japan, the Pharmaceutical and Medical Device Agency (PMDA) is responsible from the beginning of preliminary non-clinical phases through the late phases including the pivotal clinical trials.  interestingly, increasing fiscal burden and ageing society and decreasing population posing the challenges as well as emergence of unseen opportunities in Japanese pharmaceutical market. Japanese pharma economy is […]

 A great necessity of stronger alliance withlocal partner phoenixed APRO into AsianNetwork.  CROee’s Asian Network withmore country (Japan, China, Korea,Taiwan and Malaysia) to support in Asia. After aligning together withtrusted and experienced local partners enable us to support the Global Studywith more ease and professionalism. Our local partner better equipped with all required services and […]

Japan is considered to be one such country that differs greatly linguistically and culturally from Western countries. Another reason why major global pharmaceutical companies want to have Japan participate in global clinical trials is sales that can be made in Japan in the pharmaceutical market. The global pharmaceutical market is said to be worth approximately […]

1. Introduction Patient centricity is a term that is often used to mean ‘focusing on the patient’. In recent years, ‘patient centricity activities’ have come to be proactively implemented as a part of trends aiming to develop medicinal products that are more focused on patients at pharmaceutical manufacturers in Europe and America. These patient centricity […]